Avanos Medical (AVNS) Cash & Equivalents (2013 - 2026)

Avanos Medical's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $65.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.37% year-over-year to $65.6 million; the TTM figure through Mar 2026 stood at $65.6 million (down 32.37% YoY), while the FY2025 annual figure was $89.8 million, down 16.62% from the prior year.
• Cash & Equivalents came in at $65.6 million for Q1 2026 at Avanos Medical, down from $89.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q4 2022 to a low of $65.6 million in Q1 2026.
• A 5-year average of $94.5 million and a median of $92.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents climbed 27.97% in 2025 and plunged 32.37% in 2026, its largest moves.
• Avanos Medical's Cash & Equivalents stood at $127.7 million in 2022, then tumbled by 31.32% to $87.7 million in 2023, then increased by 22.81% to $107.7 million in 2024, then dropped by 16.62% to $89.8 million in 2025, then declined by 26.95% to $65.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $65.6 million, $89.8 million, and $70.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison